Tsang Benjamin

E-Card

Tsang Benjamin
Full Professor (Cross-Appointment)

Office: 613-737-8899 ext. 72926
Laboratory:: 613-737-8899 ext. 73886
Res. Admin. Assistant: 613-737-8899 ext. 72807
Fax: 613-761-4403
Email: btsang@ohri.ca

Benjamin Tsang

Biography


Biography

Ben Tsang, PhD, is Full Professor in the Department of Obstetrics & Gynaecology,  Cellular & Molecular Medicine and the Interdisciplinary School of Health Sciences, University of Ottawa. He is also Senior Scientist, Ottawa Hospital Research Institute. He completed his undergraduate training in chemistry at Bemidji State University, received MSc (Biochemistry) from the University of Iowa, and Ph.D. (Pharmacology) from the University of Ottawa. In 1980, Dr. Tsang joined the University of Ottawa as the Director, Reproductive Biology Unit and initiated a research-intensive academic program in the Department of Obstetrics and Gynaecology. He served as Associate Chair (Research) of the Department, and developed a multi-disciplinary reproductive health research program in Ottawa.  As the Director of Research of the Ottawa Civic Hospital, he played a central role in research development at the Loeb Research Institute, now one of the top health research institutions in Canada and recently named the Ottawa Hospital Research Institute.

Professor Tsang is an internationally recognized ovarian biologist, who has a successful translational research program on women’s health. His team of basic scientists and clinical investigators address important reproductive health issues, including female infertility, ovarian cancer and pregnancy complications. Dr. Tsang’s research program covers the broad area of cell fate regulation in women’s reproductive health. He and his team are examining the cell signaling pathways involved in the regulation of ovarian cell survival and apoptosis and have defined the basic mechanisms governing normal ovarian follicular growth and offered important insights into the pathophysiology of various ovarian disorders associated with infertility, including polycystic ovarian syndrome. In addition, his research on the molecular and cellular basis of chemoresistance in ovarian cancer has provided key information for the development of new therapy for chemoresistant ovarian cancer, a most lethal cancer in women. The success of Professor Tsang’s research program is also reflected by his ability to secure continuous funding from MRC/CIHR during the past 33 years, as well as support from other peer-review funding agencies, government departments, private foundations and industries. To date, he has contributed over 195 full-length original publications and 19 reviews/book chapters and issued 4 US patents. 


Selected Key Publications

  • Kim JY, Xue K, Wang Q, Liu JY, Leader A, Han JY and Tsang BK. Chemerin Suppresses Ovarian Follicular Development and Its Potential Involvement in Follicular Arrest in Rats treated Chronically with Dihydrotestosterone. Endocrinology 154: 2912–2923 (2013).
  • Wang Q, Leader A and Tsang BK. Inhibitory role of chemerin and prohibitin on FSH-induced steroidogenesis. Endocrinology 154: 956-967(2013).
  • Wang Q, Kim JY, Xue K, Liu JY, Leader A and Tsang BK. Chemerin, a novel regulator of follicular growth and steroidogenesis and its potential involvement in the pathogenesis of PCOS. Endocrinology 153: 5600-5611 (2012).
  • Xue K, Liu JY, Murphy BR and Tsang BK. Orphan nuclear receptor NR4A1 is a negative regulator of DHT-induced rat preantral follicular growth. Molecular Endocrinology 26:2004-2015 (2012).
  • Woo MG, Xue K, Liu J, McBride H, Tsang BK.  Calpain-mediated processing of p53-associated, Parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancel cells by promoting p53 subcellular trafficking.  J Biol Chem 287: 3963–3975 (2012)
  • Ali AY, Abedini MR, Tsang BK.  The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene 31: 2175-2186 (2012)
  • Leung EL, Wong JC, Johlfs MG, Tsang BK, Fiscus RR.  Protein kinase G type 1alpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation. Molec. Cancer Res 8: 578-591 (2010). 
  • Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA and Tsang, BK. Cisplatin induces p53-dependent FLICE-like inhibitory protein (FLIP) ubiquitination in ovarian cancer cells. Cancer Research 68: 4511-4517 (2008).
  • Yang X, Fraser M, Moll U. Basak A, and Tsang, BK. Akt-mediated Cisplatin resistance in Ovarian Cancer: Modulation of p53 Action on Caspase-dependent Mitochondrial Death Pathway. Cancer Research 66:3126-3136 (2006).
  • Wang HM, Jiang JY, Zhu C, Peng C and Tsang, BK. Role and Regulation of Nodal/ALK7 Signalling pathway in the control of ovarian follicular development and atresia. Molec. Endocr. 20: 2469-2482 (2006)
  • Fraser M, Chan SL, Chan SSL, Fiscus RR and. Tsang, BK. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells. Oncogene 25:2203-2212 (2006).
  • Orisaka M, Orisaka S, Jiang J-Y, Craig J, Wang Y, Kotsuji F and Tsang, BK. Growth Differentiation Factor-9 is anti-apoptotic during follicular development from preantral to early antral stage. Molec. Endocr. 20: 2456-2468 (2006).
  • Qiu Q, Yang M, Basak A, Mbikay M, Tsang, BK, Gruslin A. ProIGF-II processing in the human placenta: The expression and role of the proprotein convertase PC4. Proc Nat. Acad. Sci. USA 102: 11047-11052 (2005).
  • Dan HC, Sun M, Kaneko S, Feldman RI., Nicosia SV, Wang HG, Tsang, BK, Cheng JQ. Akt Phosphorylation and Stabilization of XIAP. J. Biol. Chem. 279: 5405-5412 (2004).
  • Abedini MR., Qiu Q, Yan X and Tsang, BK. Possible Role of FLICE-Like Inhibitory Protein (FLIP) in Chemoresistant Ovarian Cancer Cells in vitro. Oncogene 24: 6977-7004 (2004).
  • Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ and Tsang, BK. p53 is a determinant in Xiap/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Research 63: 7081-7088 (2003).
  • Asselin E, Mills GB and Tsang, BK. Xiap regulates AKT activity and its caspase 3- dependent cleavage during cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Research 61: 1862-1868 (2001).
  • Sasaki H, Sheng Y, Kotsuji F and Tsang, BK. (2000). Down-regulation of Xiap induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Research 60: 5659-5666.

Recent Publications (2008- Present)

  • Orisaka M, Hattori K, Fukuda S, Mizutani T, Miyamoto K, Tsang BK, Kotsuji F and Yoshida Y. Dysregulation of ovarian follicular development:  LH decreases FSH sensitivity during preantral-early antral transition. Endocrinology (2013, In press)
  • Farrand L, Byun S, Kim JY, Im-Aram A, Lee JH, LimS, Lee KW, Suh JY, Lee HJ and Tsang BK. Piceatannol enhances cisplatin sensitivity in ovarian cancer through modulation of the p53 tumor suppressor pathway and induction of mitochondrial fission. J. Biol. Chem. (2013, In Press)
  • Hossain M, Cao M, Wang Q, Kim JY, Schellander K, Tesfaye D, and Tsang BK. Altered expression of miRNAs in a dihydrotestosterone-induced rat PCOS model. J Ovarian Research 6:36 (2013)
  • Wang Q, Leader A and Tsang BK. Role and Regulation of prohibitin during ovarian follicular development. J Ovarian Research 6:23 (2013).
  • Han YY, Xia GL and Tsang BK. Regulation of Cyclin D2 Expression and Degradation by Follicle Stimulating Hormone during Rat Granulosa Cell Proliferation in vitro. Biol Reprod. 88: 1-11 (2013)
  • Du MR, Qiu Q, Gruslin A, Gordon J, Li DJ and Tsang BK. SB225002 promotes mitotic catastrophe in chemo-sensitive and –resistant ovarian cancer cells independent of p53 status in vitro. PLOS ONE 8 (1): e54572 (2013)
  • Kobayashi N, Abedini MR, Sakuragi N and Tsang BK. PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation. J Ovarian Research 6: 7(2013).
  • Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ and Tsang BK. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann NY Acad Sci 1271:58-67 (2012)
  • Al-Bahlani S, Fraser M, Wong AY, Sayan BS, Bergeron R, Melino G, Tsang BK. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene 30:4219-4230 (2011)
  • Haider M, Qiu Q, Bani-Yaghoub M, Tsang BK, Gruslin A.  Characterization and role of NUMB in the human extravillous trophopblast.  Placenta 32: 441-449 (2011).
  • Leung EL, Wong JC, Johlfs MG, Tsang BK, Fiscus RR.  Protein kinase G type 1alpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation. Mol Cancer Res. 8: 578-591 (2010)
  • Fu J, Lv X, Lin H, Wu L, Wang R,  Zhou Z, Zhang B, Wang YL, Tsang BK, Zhu C, Wang H.  Ubiquitin ligase cullin 7 induces epithelial-mesenchymal transition in human choriocarcinoma cells. J Biol Chem. 285:10870-10879 (2010)
  • Orisaka M, Jiang J-Y, Orisaka S, Kotsuji F, Tsang BK.   Growth Differentiation Factor-9 promotes rat preantral follicle growth by    up-regulating follicular androgen biosynthesis.  Endocrinology 150: 2740-2748(2009). 
  • Gregory-Bass RC, Olatinwo M , Xu W, Matthews R, Stiles JK, Thomas K, Liu D, Tsang, BK and Thompson WE. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Internat. J. Cancer 122: 1923-1930 (2008)
  • Leung LH, Fraser M, Fiscus RR and Tsang, BK. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance. Br. J. Cancer 98, 1803 - 1809 (2008)
  • Fraser M, Bai T and Tsang, BK. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Internat. J Cancer. 122:534-546 (2008)
  • Yang X, Fraser M, Abedini MR, Bai T and Tsang, BK. Regulation of AIF-Mediated, Cisplatin-Induced Apoptosis by Akt. Br. J. Cancer 98: 803-808 (2008).

Back to top